about
The Sin3a repressor complex is a master regulator of STAT transcriptional activityIn vivo inhibition of anti-hepatitis B virus core antigen (HBcAg) immunoglobulin G production by HBcAg-specific CD4(+) Th1-type T-cell clones in a hu-PBL-NOD/SCID mouse modelVaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infectionScavenger receptor BI and BII expression levels modulate hepatitis C virus infectivityAnimal models for the study of HCVImpact of lipids and lipoproteins on hepatitis C virus infection and virus neutralizationMouse Systems to Model Hepatitis C Virus Treatment and Associated ResistanceCell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitroCell Culture Adaptation of Hepatitis C Virus and In Vivo Viability of an Adapted VariantRole of the Hepatitis C Virus Core+1 Open Reading Frame and Core cis-Acting RNA Elements in Viral RNA Translation and ReplicationProduction of Infectious Genotype 1b Virus Particles in Cell Culture and Impairment by Replication Enhancing MutationsDiscovery of (7R)-14-cyclohexyl-7-{[2-(dimethylamino)ethyl](methyl) amino}-7,8-dihydro-6H-indolo[1,2-e][1,5]benzoxazocine-11-carboxylic acid (MK-3281), a potent and orally bioavailable finger-loop inhibitor of the hepatitis C virus NS5B polymeraseArtemisinin analogues as potent inhibitors of in vitro hepatitis C virus replicationCombined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses.Sporozoite immunization of human volunteers under chemoprophylaxis induces functional antibodies against pre-erythrocytic stages of Plasmodium falciparum.Lipoprotein lipase inhibits hepatitis C virus (HCV) infection by blocking virus cell entryViral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantationChallenge pools of hepatitis C virus genotypes 1-6 prototype strains: replication fitness and pathogenicity in chimpanzees and human liver-chimeric mouse models.Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice.Prevention of hepatitis B infections: vaccination and its limitations.Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agentsImmune suppression uncovers endogenous cytopathic effects of the hepatitis B virusHypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralizationA genetically attenuated malaria vaccine candidate based on P. falciparum b9/slarp gene-deficient sporozoitesIn vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus.Detection and structural investigation of metabolites of stanozolol in human urine by liquid chromatography tandem mass spectrometry.Generation and characterization of small single domain antibodies inhibiting human tumor necrosis factor receptor 1.Griffithsin has antiviral activity against hepatitis C virusClearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibodyA human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo.Flunarizine prevents hepatitis C virus membrane fusion in a genotype-dependent manner by targeting the potential fusion peptide within E1.The human liver-uPA-SCID mouse: a model for the evaluation of antiviral compounds against HBV and HCV.Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C VirusExpanding the Host Range of Hepatitis C Virus through Viral Adaptation.HVR1-mediated antibody evasion of highly infectious in vivo adapted HCV in humanised mice.HCV animal models: a journey of more than 30 years.Hepatitis C virus infection and related liver disease: the quest for the best animal modelHCV animal models and liver disease.Development and application of hepatitis C reporter viruses with genotype 1 to 7 core-nonstructural protein 2 (NS2) expressing fluorescent proteins or luciferase in modified JFH1 NS5A.Is hepatitis E virus an emerging problem in industrialized countries?
P50
Q24292983-601B84A2-F849-4523-970A-A85B825745A0Q24529209-D53C1BBF-EFE6-4054-A86E-EF06C6FD7210Q24628167-26CF5D88-3953-411D-80C0-3F3F37951A97Q24672232-FDCAEE23-138A-4A91-9DA9-FB6F786C69F1Q26797836-418D0A5F-48E6-492B-974F-C04E0ED0DD1AQ26864485-CFF96D9A-5524-4B83-A6E7-B5119B13F43BQ27469038-6A9986EF-82E4-4B61-BC12-E4D609A85206Q27473436-F32FB496-1EEE-49CA-A3DF-F9A5D628EC94Q27485033-22E46353-2CBE-4511-A334-B7C1219E8A69Q27487337-FC193553-437B-4E40-BBEC-D13883D608FAQ27488616-78D15AA1-C6DF-4647-8D56-C03A4227A549Q27666224-07A03ECE-E345-4544-BB9A-8871B5AA0F1CQ28536780-EF4CE86A-23E0-4BBC-B259-86ABAC672D3BQ33602744-E81AE829-FA49-465E-B446-D10805FDCB7AQ33960093-B7686FE2-7924-4EC7-8236-D6BE90E6C97FQ34062532-A408990A-08D1-4E4A-B0E6-A814CC0E8EA1Q34096483-0E1D8AD8-5DC4-422C-AAEE-F89A4070CD71Q34140014-8CDF46FC-35B7-422B-8803-70683E4660DAQ34194575-AD8AD629-573D-43CE-83B7-7E40C1B90C7FQ34402540-251D06AF-0DA4-4306-8A32-0F919C421870Q34416004-148222DB-3819-4EDF-955B-D9C50C35B607Q34434897-2B06DDAD-D900-43EB-AFBC-F865CE92E4D9Q34741652-0C8EA9DA-64BB-43EF-B32B-68AB46F8C278Q34753532-B51208D2-6CA5-4284-8C6B-48459EC556A8Q34816677-14A682DD-9C95-4184-896D-065FF446E9AFQ34982673-3E67056B-4973-4F24-B576-F20EBCEBBA25Q35080243-BFB15641-0498-4B7D-8E1F-A9C6B721F775Q35363633-210148E4-6CAD-43F7-B86D-7CA37AC7F12EQ35602284-AC2CFE32-914A-4039-8EDF-709E9C5E6FA0Q35685409-9AF1D2F0-4086-450E-A570-EFD6A9711364Q35739094-EC68E8D1-DD6E-4DE1-B053-C2C28810754FQ37245018-7F1C0BD6-1729-4C5A-AEA3-BB71C7109DC5Q37252935-7F12AE43-D7A1-4173-9D4F-E305BB71CFD5Q37402299-3B0F4E84-1D5B-4F96-9EC9-82F30E5D69F4Q37471718-3B74C958-7E8E-4B30-B026-76582ED35567Q37945172-2B9232E4-69D2-451A-9FF9-7A94D3F5EF85Q38125192-2B298E8A-F5AA-4150-A4FB-4E6B60F37601Q38274455-6D15AD72-28AE-41C4-B589-AB562C41B230Q38286335-3FC0D536-FCA1-426D-A99B-A631C3348E9AQ38547282-16DEF8BD-0CF4-4AA4-A95C-6F0EC5BB09E4
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Philip Meuleman
@ast
Philip Meuleman
@en
Philip Meuleman
@es
Philip Meuleman
@nl
Philip Meuleman
@sl
type
label
Philip Meuleman
@ast
Philip Meuleman
@en
Philip Meuleman
@es
Philip Meuleman
@nl
Philip Meuleman
@sl
prefLabel
Philip Meuleman
@ast
Philip Meuleman
@en
Philip Meuleman
@es
Philip Meuleman
@nl
Philip Meuleman
@sl
P1053
H-2899-2013
P106
P21
P31
P3829
P496
0000-0001-6821-234X